Humana Inc

Humana Inc. faces mixed investor sentiment—net sell‑side pressure and neutral analyst outlook—while its core health‑care strengths remain intact.

Humana shares plunge 20% after Medicare Advantage payment update, while the insurer launches a $3 M scholarship fund—impacting investors and future policy outlook.

Humana shares plunge 20% amid market sell‑off, yet company launches $3 M scholarship fund, signaling long‑term value for investors.

Humana expands Medicare Advantage oncology care by partnering with Atlas Oncology, improving access and outcomes for seniors while boosting its managed‑care portfolio.

Humana’s earnings, Jefferies upgrade, and a new partnership with Cost Plus Drugs aim to boost Medicare pharmacy costs and investor confidence.

Humana Inc. stock rose 10.77% in 2025, closing near its 52‑week high, with a $34.35 bn market cap and 21.92 P/E—stable gains for health‑care investors.

Humana Inc. has partnered with Healthcare Outcomes Performance Company (HOPCo) to expand its Musculoskeletal Population Health program in Arizona, leveraging digital engagement tools and integrated analytics to enhance care quality and optimize heal…

Humana Inc. has demonstrated a decade of robust performance in the managed health care sector, driven by its strategic positioning, operational excellence, and commitment to innovation, positioning it for continued growth and success.

A US District Judge has upheld a Centers for Medicare & Medicaid Services (CMS) decision to downgrade Humana’s Medicare Advantage star ratings, potentially resulting in billions of dollars in lost revenue for the company.

Humana Inc. has driven momentum in the S&P 500 with a 6.2% surge, fueled by its strategic expansion of Medicare offerings and cost-control initiatives, which have reinforced investor confidence in the company’s growth prospects.